查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474029

头颈鳞状细胞癌的细胞疗法 - 研发管线分析：2024 年

Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics 2024
出版日期: | 出版商: Mellalta Meets LLP | 英文 109 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

过继性细胞疗法（ACT）在多种癌症的早期试验中显示出有希望的结果。然而，治疗头颈鳞状细胞癌（HNSCC）的成功方法面临实体瘤常见的独特课题。这些课题包括需要为 T 细胞建立适当的归巢机制，以有效地靶向肿瘤，确保肿瘤内有足够的 T 细胞浸润以产生强大的免疫反应，并且这包括识别不会对肿瘤产生影响的抗原。儘管 ACT 治疗 HNSCC 仍处于起步阶段，但人们乐观地认为，它将在不久的将来在治疗中发挥重要作用。这与检查点抑制剂合併用于化疗难治性患者和復发转移的第一线治疗具有潜力。

根据我们的分析，正在开发的细胞疗法有多种可以帮助治疗 HNSCC，包括 TCR T 细胞疗法、肿瘤浸润淋巴细胞 (TIL) 以及与免疫检查点抑制剂 (ICIs) 的联合疗法。

本报告探讨了头颈鳞状细胞癌的细胞疗法，包括市场机会、关键竞争分析、公司管道药物概况、临床试验和其他进展。

目录

第一章 报告概述

第2章 头颈鳞状细胞癌（HNSCC）细胞治疗标靶背景

  • 头颈部鳞状细胞癌 (HNSCC) 的过继性细胞疗法
  • 过继细胞疗法的类型
  • 头颈鳞状细胞癌的CAR-T疗法
  • CAR-NK细胞治疗头颈鳞状细胞癌
  • TCR T细胞治疗头颈鳞状细胞癌
  • TIL治疗头颈鳞状细胞癌

第三章 头颈鳞状细胞癌（HNSCC）细胞治疗的管线分析

第四章临床试验与研究

  • 头颈鳞状细胞癌的细胞疗法临床试验（依地区）
  • HNSCC细胞治疗单药治疗及合併治疗临床试验
  • 临床和监管时间表
  • 后期概况比较概述

第五章授权、收购和合作

第六章 管道情况

  • HNSCC 管道中细胞疗法的药物概况 - 概述
  • 第二阶段
  • 一期/二期
  • 第一阶段
  • 临床前
  • 药物发现

第7章 HNSCC细胞治疗的SWOT分析

第8章附录

简介目录

The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.

In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.

As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.

The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.

To be continued...

Report Coverage:

Indication Prioritization: HNSCC market potential

Business Transactions & Strategies: Key collaborations and deal values

HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results

HNSCC Cell Therapies Acquisition Targets

HNSCC Cell Therapies Competitive Intelligence

Recent and upcoming events

Table of Content

1.Report Overview

2.The Cell Therapies in HNSCC Target Background

  • 2.1.Adoptive Cell Therapies in HNSCC
  • 2.2.Types of Adoptive Cell Therapies
  • 2.3.CAR-T Therapy in HNSCC
  • 2.4.CAR-NK cell therapy in HNSCC
  • 2.5.TCR T-cell therapy in HNSCC
  • 2.6.TIL Therapy in HNSCC

3.Cell Therapies in HNSCC Pipeline Analysis

  • 3.1.Development Overview
  • 3.2.Pipeline Products by Stage of Development
  • 3.3.Cell Therapies in HNSCC Competitive Landscape
  • 3.4.Pipeline Products by Company and Region
  • 3.5.Type of Cell Therapies in HNSCC Pipeline Landscape

4.Clinical Trials and Research

  • 4.1.Cell Therapies Clinical Trials in HNSCC by Region
  • 4.2.HNSCC Cell therapies Monotherapy & Combinations Clinical Trials
  • 4.3.Clinical & Regulatory Timelines
  • 4.4.Late-Stage Profiles Comparisons At-a-glance

5.Licensing, Acquisition, and Collaboration

  • 5.1.Cell Therapies in HNSCC Licensing, Acquisition, and Deal Values
  • 5.2.Licensing by Transaction Type and Total Amount Size by Phases

6.Pipeline Landscape

  • 6.1.Cell Therapies in HNSCC Pipeline Drug Profiles- at a glance
  • 6.2.Phase II
    • 6.2.1.LN-145
      • 6.2.1.1.Product Profile
      • 6.2.1.2.Clinical Trial Details
    • 6.2.2.PD-L1 T-haNK
      • 6.2.2.1.Product Profile
      • 6.2.2.2.Clinical Trial Details
  • 6.3.Phase I/II
    • 6.3.1.RAPA-201
      • 6.3.1.1.Product Profile
      • 6.3.1.2.Clinical Trial Details
    • 6.3.2.EBV TCR-T
      • 6.3.2.1.Product Profile
      • 6.3.2.2.Clinical Trial Details
    • 6.3.3.IMA402
      • 6.3.3.1.Product Profile
      • 6.3.3.2.Clinical Trial Details
  • 6.4.Phase I
    • 6.4.1.HRYZ-T101
      • 6.4.1.1.Product Profile
      • 6.4.1.2.Clinical Trial Details
    • 6.4.2.TSC-200-A0201
      • 6.4.2.1.Product Profile
      • 6.4.2.2.Clinical Trial Details
    • 6.4.3.P-MUC1C-ALLO1
      • 6.4.3.1.Product Profile
      • 6.4.3.2.Clinical Trial Details
    • 6.4.4.NT-175
      • 6.4.4.1.Product Profile
      • 6.4.4.2.Clinical Trial Details
    • 6.4.5.TSC-201-B0702
      • 6.4.5.1.Product Profile
      • 6.4.5.2.Clinical Trial Details
    • 6.4.6.Uzatresgene autoleucel
      • 6.4.6.1.Product Profile
      • 6.4.6.2.Clinical Trial Details
    • 6.4.7.TSC-203-A0201
      • 6.4.7.1.Product Profile
      • 6.4.7.2.Clinical Trial Details
    • 6.4.8.TSC-204-A0201
      • 6.4.8.1.Product Profile
      • 6.4.8.2.Clinical Trial Details
    • 6.4.9.TSC-204-C0702
      • 6.4.9.1.Product Profile
      • 6.4.9.2.Clinical Trial Details
    • 6.4.10.TSC-204-A0101
      • 6.4.10.1.Product Profile
      • 6.4.10.2.Clinical Trial Details
    • 6.4.11.TBio-4101
      • 6.4.11.1.Product Profile
      • 6.4.11.2.Clinical Trial Details
    • 6.4.12.CRTE7A2
      • 6.4.12.1.Product Profile
      • 6.4.12.2.Clinical Trial Details
    • 6.4.13.AGX-148
      • 6.4.13.1.Product Profile
      • 6.4.13.2.Clinical Trial Details
    • 6.4.14.NEXI-003
      • 6.4.14.1.Product Profile
      • 6.4.14.2.Clinical Trial Details
    • 6.4.15.IMA401
      • 6.4.15.1.Product Profile
      • 6.4.15.2.Clinical Trial Details
    • 6.4.16.WU-NK-101
      • 6.4.16.1.Product Profile
      • 6.4.16.2.Clinical Trial Details
    • 6.4.17.IMA203
      • 6.4.17.1.Product Profile
      • 6.4.17.2.Clinical Trial Details
    • 6.4.18.IMA-203CD8
      • 6.4.18.1.Product Profile
      • 6.4.18.2.Clinical Trial Details
  • 6.5.Preclinical
    • 6.5.1.ADP-600
    • 6.5.2.IMA204
  • 6.6.Discovery
    • 6.6.1.TSC-200-C0702
    • 6.6.2.TSC-201-A0201
    • 6.6.3.TSC-201-A2402
    • 6.6.4.TSC-202-A0201
    • 6.6.5.TSC-203-B0702
    • 6.6.6.TSC-204-A0301
    • 6.6.7.TSC-204-B0702
    • 6.6.8.TSC-203-A2402

7.Cell Therapies in HNSCC SWOT Analysis

8.Appendix

  • 8.1.About us